Optional product analytics
With your permission, we use privacy-limited analytics to understand which research journeys work. We do not run advertising trackers or session replay. You can change this choice in Preferences. Read the Privacy Policy.
Pfizer Inc.'s published Reduce conclusion compares the analysis-date price with fair value and potential value. Read the full report for assumptions, evidence, and material risks.
| Market cap | $161.9B | |
|---|---|---|
| Revenue (ttm) | 63.7B | |
| Net income (ttm) | 4.3B | |
| EPS (ttm) | $0.76 | |
| Shares out | 5.7B | |
| P/E (trailing) | 38.8x | |
| P/E (forward) | 9.7x | |
| Dividend | $1.72 (5.86%) | |
| Volume | 20,724,989 | |
| Beta | 0.28 |
Recent price action with selectable time range.
| Item | P1 | P2 | P3 | P4 | P5 | Trend |
|---|---|---|---|---|---|---|
| Period | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 | Trend |
| Revenue | $73.64B | $91.79B | $50.91B | $63.63B | $62.58B | -4.0% |
| Gross profit | $46.88B | $62.09B | $30.34B | $41.85B | $44.01B | -1.6% |
| Operating income | $25.60B | $35.97B | $3.27B | $11.11B | $10.19B | -20.6% |
| Net income | $21.98B | $31.37B | $2.12B | $8.03B | $7.77B | -22.9% |
| EPS (diluted) | $3.85 | $5.47 | $0.37 | $1.41 | $1.36 | -22.9% |
| EBITDA | $30.79B | $41.03B | $9.56B | $18.13B | $15.10B | -16.3% |
| R&D | $13.83B | $11.43B | $10.58B | $10.74B | $11.98B | -3.5% |
| SG&A | $12.70B | $13.68B | $14.77B | $14.73B | $13.79B | +2.1% |
Recent company headlines from major financial publishers.
The Base scenario reflects the modal expected operating trajectory. Management delivers planned net cost savings across manufacturing and corporate functions, successfully stabilizing operating margins at normalized levels. However, patent expirations on core mature blockbusters cause moderate revenue contraction before pipeline launches take effect post-transition. Capital allocation remains dedicated to debt reduction and dividend maintenance. This path targets $25.83 with an estimated probability of 60.0%, representing a return of -9.9% from $28.67 to Fair value of $25.83. This path is confirmed by revenue tracking guided ranges and leverage declining steadily toward target levels.
Under the Bull scenario, Pfizer accelerates execution of its operational cost reduction program while commercial oncology launches exceed expectations. Operating margins expand beyond normalized levels as manufacturing efficiencies take hold. Label expansions in oncology and promising early data from metabolic combination trials catalyze multiple expansion toward peer averages. This path targets $28.85 with an estimated probability of 20.0%, offering an expected return of 0.6% compared to $28.67. Investors would confirm this path through consecutive quarters of margin outperformance and clinical label expansions by FY2027.
| Ke ↓ / g → | 1.0% | 1.5% | 2.0% | 2.5% | 3.0% |
|---|---|---|---|---|---|
| 6.3% | $26.4 | $26.4 | $26.4 | $26.4 | $26.4 |
| 6.8% | $26.1 | $26.1 | $26.1 | $26.1 | $26.1 |
| 7.3% | $25.8 | $25.8 | $25.8 | $25.8 | $25.8 |
| 7.8% | $25.6 | $25.6 | $25.6 | $25.6 | $25.6 |
| 8.3% | $25.3 | $25.3 | $25.3 | $25.3 | $25.3 |
Upcoming earnings date and setup when available.
The rating each month's published research edition carried. A rating compares the price at analysis with the Fair value; it is not a record of whether the call was right.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 |
